

Sonia Dollfus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5291922/publications.pdf>

Version: 2024-02-01

115
papers

3,724
citations

186265

28
h-index

138484

58
g-index

129
all docs

129
docs citations

129
times ranked

4101
citing authors

#	ARTICLE	IF	CITATIONS
1	The priming effect of repetitive transcranial magnetic stimulation on clinical response to electroconvulsive therapy in treatment-resistant depression: a randomized, double-blind, sham-controlled study. <i>Psychological Medicine</i> , 2023, 53, 2060-2071.	4.5	6
2	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	2.6	13
3	A web-based adapted physical activity program (e-APA) versus health education program (e-HE) in patients with schizophrenia and healthy volunteers: study protocol for a randomized controlled trial (PEPSY V@Si). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 325-337.	3.2	4
4	A new 3-hit mouse model of schizophrenia built on genetic, early and late factors. <i>Schizophrenia Research</i> , 2021, 228, 519-528.	2.0	11
5	Clinical features and outcomes of COVID-19 patients hospitalized for psychiatric disorders: a French multi-centered prospective observational study. <i>Psychological Medicine</i> , 2021, , 1-9.	4.5	4
6	Negative symptoms in schizophrenia: correlation with clinical and genetic factors. <i>Pharmacogenomics</i> , 2021, 22, 389-399.	1.3	1
7	Common mechanisms involved in manic switch and pain relief induced by lamotrigine: A case report and a literature review. <i>L'Encephale</i> , 2021, 47, 235-237.	0.9	2
8	Validity and reliability of a Persian version of the self- evaluation of negative symptoms (SNS). <i>BMC Psychiatry</i> , 2021, 21, 516.	2.6	1
9	Validation of the lithuanian version of the self-evaluation of negative symptoms scale (SNS). <i>Nordic Journal of Psychiatry</i> , 2021, 75, 351-355.	1.3	5
10	Examining transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia (STIMâ€™Zo): a study protocol for a multicentre, double-blind, randomized sham-controlled clinical trial. <i>Trials</i> , 2021, 22, 964.	1.6	7
11	M15. MORPHOLOGY OF THE SUPERIOR TEMPORAL SULCUS IN PATIENTS WITH SCHIZOPHRENIA: A MARKER OF GENETIC OR ENVIRONMENTAL VULNERABILITY?. <i>Schizophrenia Bulletin</i> , 2020, 46, S138-S139.	4.3	0
12	A new toolbox to compare target localizations for non-invasive brain stimulation: An application of rTMS treatment for auditory hallucinations in schizophrenia. <i>Schizophrenia Research</i> , 2020, 223, 305-310.	2.0	2
13	Impact cÃ©rÃ©bral structurel et fonctionnel de la Clozapine chez les patients souffrant de schizophrÃ©nie : revue systÃ©matique des Ã©tudes longitudinales en neuroimagerie: Structural and functional impact of clozapine in patients with schizophrenia: systematic review of neuroimaging longitudinal studies. <i>Canadian Journal of Psychiatry</i> , 2020, 66, 070674372096645.	1.9	0
14	Validation of the Arabic version of the "self-evaluation of negative symptoms" scale (SNS). <i>BMC Psychiatry</i> , 2020, 20, 240.	2.6	10
15	GeodesicSlicer: a Slicer Toolbox for Targeting Brain Stimulation. <i>Neuroinformatics</i> , 2020, 18, 509-516.	2.8	4
16	Cortical Thickness and Natural Scene Recognition in the Childâ€™s Brain. <i>Brain Sciences</i> , 2020, 10, 329.	2.3	0
17	Anatomical Connectivity of the Visuospatial Attentional Network in Schizophrenia: A Diffusion Tensor Imaging Tractography Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 266-273.	1.8	7
18	The patientsâ€™ view. , 2020, , 51-66.		3

#	ARTICLE	IF	CITATIONS
19	<p>Auditory verbal hallucinations in schizophrenia: current perspectives in brain stimulation treatments</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2105-2117.	2.2	15
20	Specificity and sensitivity of the Self-assessment of Negative Symptoms (SNS) in patients with schizophrenia. Schizophrenia Research, 2019, 211, 51-55.	2.0	19
21	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology, 2019, 29, 947-959.	0.7	60
22	Corpus callosum microstructural and macrostructural abnormalities in schizophrenia according to the stage of disease. Psychiatry Research - Neuroimaging, 2019, 291, 63-70.	1.8	13
23	Social cognition in schizophrenia: Validation of an ecological fMRI task. Psychiatry Research - Neuroimaging, 2019, 286, 60-68.	1.8	5
24	Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population. BMC Psychiatry, 2019, 19, 327.	2.6	21
25	Dandy-Walker Malformation-Like Condition Revealed by Refractory Schizophrenia: A Case Report and Literature Review. Neuropsychobiology, 2019, 77, 59-66.	1.9	11
26	Theta burst stimulation on social cognition and N-Acetyl aspartate in two patients with schizophrenia. Psychiatry Research - Neuroimaging, 2018, 274, 31-32.	1.8	1
27	Fronto-subcortical functional connectivity in patients with schizophrenia and bipolar disorder during a verbal fluency task. World Journal of Biological Psychiatry, 2018, 19, S124-S132.	2.6	6
28	High-Frequency Neuronavigated rTMS in Auditory Verbal Hallucinations: A Pilot Double-Blind Controlled Study in Patients With Schizophrenia. Schizophrenia Bulletin, 2018, 44, 505-514.	4.3	37
29	S167. ANATOMICAL CONNECTIVITY OF THE VISUOSPATIAL ATTENTIONAL NETWORK IN SCHIZOPHRENIA: A DTI-BASED TRACTOGRAPHY STUDY. Schizophrenia Bulletin, 2018, 44, S390-S390.	4.3	0
30	Effects of low- and high-frequency repetitive transcranial magnetic stimulation on long-latency auditory evoked potentials. Neuroscience Letters, 2018, 686, 198-204.	2.1	7
31	Mobile Intensive Care Unit: A case management team dedicated to early psychosis in France. Microbial Biotechnology, 2018, 12, 995-999.	1.7	7
32	Abnormalities of fronto-subcortical pathways in schizophrenia and the differential impacts of antipsychotic treatment: a DTI-based tractography study. Psychiatry Research - Neuroimaging, 2018, 280, 22-29.	1.8	19
33	S183. ABNORMALITIES OF FRONTO-SUBCORTICAL PATHWAYS IN SCHIZOPHRENIA AND THE DIFFERENTIAL IMPACTS OF ANTIPSYCHOTIC TREATMENT: A DTI-BASED TRACTOGRAPHY STUDY. Schizophrenia Bulletin, 2018, 44, S396-S396.	4.3	0
34	Sulcal Polymorphisms of the IFC and ACC Contribute to Inhibitory Control Variability in Children and Adults. ENeuro, 2018, 5, ENEURO.0197-17.2018.	1.9	25
35	Current developments and challenges in the assessment of negative symptoms. Schizophrenia Research, 2017, 186, 8-18.	2.0	75
36	Impact of rTMS on functional connectivity within the language network in schizophrenia patients with auditory hallucinations. Schizophrenia Research, 2017, 189, 142-145.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Network modeling of resting state connectivity points towards the bottom up theories of schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2017, 266, 19-26.	1.8	12
38	Abnormalities of language pathways in schizophrenia patients with and without a lifetime history of auditory verbal hallucinations: A DTI-based tractography study. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 528-538.	2.6	19
39	Relationships between corpus callosum and language lateralization in patients with schizophrenia and bipolar disorders. <i>Bipolar Disorders</i> , 2017, 19, 496-504.	1.9	13
40	Negative symptoms: History of the concept and their position in diagnosis of schizophrenia. <i>Schizophrenia Research</i> , 2017, 186, 3-7.	2.0	41
41	Theta burst stimulation on medial prefrontal cortex in schizophrenia patients with impaired social cognition: a pilot 1H-MRS study. <i>European Neuropsychopharmacology</i> , 2017, 27, S955-S956.	0.7	0
42	Efficacy of high-frequency neuronavigated repetitive TMS in auditory verbal hallucinations: a double-blind controlled study in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2017, 27, S957.	0.7	0
43	Functional deficit of the medial prefrontal cortex during emotional sentence attribution in schizophrenia. <i>Schizophrenia Research</i> , 2016, 178, 86-93.	2.0	10
44	Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. <i>Schizophrenia Bulletin</i> , 2016, 42, 571-578.	4.3	100
45	Placebo Response in Repetitive Transcranial Magnetic Stimulation Trials of Treatment of Auditory Hallucinations in Schizophrenia: A Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 301-308.	4.3	40
46	Neuroleptic malignant syndrome and catatonia overlapping: 2 case reports. <i>Psychopharmacology</i> , 2015, 232, 2643-2644.	3.1	5
47	Left-hemisphere lateralization for language and interhemispheric fiber tracking in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 165, 30-37.	2.0	28
48	Functional and structural brain asymmetries in patients with schizophrenia and bipolar disorders. <i>Schizophrenia Research</i> , 2015, 161, 210-214.	2.0	40
49	Cortical Anatomical Variations and Efficacy of rTMS in the Treatment of Auditory Hallucinations. <i>Brain Stimulation</i> , 2015, 8, 1162-1167.	1.6	29
50	How do high- and low-frequency repetitive transcranial magnetic stimulations modulate the temporal cortex. <i>Psychophysiology</i> , 2015, 52, 192-198.	2.4	5
51	Social Cognition in Schizophrenic Patients: The Effect of Semantic Content and Emotional Prosody in the Comprehension of Emotional Discourse. <i>Frontiers in Psychiatry</i> , 2014, 5, 120.	2.6	14
52	Left fronto-temporal dysconnectivity within the language network in schizophrenia: An fMRI and DTI study. <i>Psychiatry Research - Neuroimaging</i> , 2014, 223, 261-267.	1.8	35
53	Functional and white matter abnormalities in the language network in patients with schizophrenia: A combined study with diffusion tensor imaging and functional magnetic resonance imaging. <i>Schizophrenia Research</i> , 2013, 150, 93-100.	2.0	15
54	Functional hemispheric lateralization for language in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 149, 42-47.	2.0	28

#	ARTICLE	IF	CITATIONS
55	Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia. <i>Schizophrenia Research</i> , 2013, 148, 74-80.	2.0	158
56	Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) on Brain Functional Marker of Auditory Hallucinations in Schizophrenia Patients. <i>Brain Sciences</i> , 2013, 3, 728-743.	2.3	11
57	Distinct Episodic Verbal Memory Profiles in Schizophrenia. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2013, 3, 192-205.	2.1	7
58	Reduced functional cerebral lateralization: a biomarker of schizophrenia?. <i>Bipolar Disorders</i> , 2013, 15, 449-451.	1.9	6
59	Speech Processing and Auditory Hallucinations. , 2013, , 123-135.		2
60	Comment on Milanovic et al.. <i>Schizophrenia Research</i> , 2012, 134, 293.	2.0	0
61	Reproducibility of fMRI activations during a story listening task in patients with schizophrenia. <i>Schizophrenia Research</i> , 2011, 128, 98-101.	2.0	17
62	Repetitive transcranial magnetic stimulation in the treatment of auditory hallucinations in schizophrenic patients. <i>Current Opinion in Psychiatry</i> , 2011, 24, 533-540.	6.3	23
63	Neural networks for emotional discourse comprehension in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2011, 26, e116-e117.	1.7	0
64	Language lateralization in left-handed patients with schizophrenia. <i>Neuropsychologia</i> , 2011, 49, 313-319.	1.6	17
65	Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline. <i>Evidence-Based Mental Health</i> , 2011, 14, 79-79.	4.5	1
66	Valproate-induced encephalopathy related to concurrent antimanic medications. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E22-3.	1.8	0
67	Use of Clozapine in an Adolescent With Refractory First-Episode Psychosis and Neutropenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 336-338.	1.4	4
68	Meaningfulness and globalâ€“local processing in schizophrenia. <i>Neuropsychologia</i> , 2010, 48, 3062-3068.	1.6	14
69	Functional deficit in the medial prefrontal cortex in patients with chronic schizophrenia, first psychotic episode, and bipolar disorders. <i>Bipolar Disorders</i> , 2010, 12, 450-452.	1.9	8
70	Impact of cognitive performance on the reproducibility of fMRI activation in schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 378-389.	2.4	13
71	Impaired Smooth Pursuit in Schizophrenia Results from Prediction Impairment Only. <i>Biological Psychiatry</i> , 2010, 67, 992-997.	1.3	22
72	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009, 166, 675-682.	7.2	284

#	ARTICLE	IF	CITATIONS
73	Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study. <i>International Clinical Psychopharmacology</i> , 2009, 24, 34-41.	1.7	25
74	Approches cliniques et diagnostiques des premiers Ã©pisodes psychotiques. <i>Annales Medico-Psychologiques</i> , 2009, 167, 79-85.	0.4	3
75	Les antipsychotiques lors d'un premier Ã©pisode psychotique. <i>Annales Medico-Psychologiques</i> , 2009, 167, 86-92.	0.4	0
76	Approche cognitivocomportementale des patients prÃ©sentant un premier Ã©pisode psychotique. <i>Annales Medico-Psychologiques</i> , 2009, 167, 158-166.	0.4	4
77	Two-day treatment of auditory hallucinations by high frequency rTMS guided by cerebral imaging: A 6-month follow-up pilot study. <i>Schizophrenia Research</i> , 2009, 113, 77-83.	2.0	79
78	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. <i>Schizophrenia Research</i> , 2009, 115, 104-114.	2.0	102
79	Functional deficit in the medial prefrontal cortex during a language comprehension task in patients with schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 304-311.	2.0	29
80	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>Lancet</i> , The, 2008, 371, 1085-1097.	13.7	964
81	Treatment of auditory hallucinations by combining high-frequency repetitive transcranial magnetic stimulation and functional magnetic resonance imaging. <i>Schizophrenia Research</i> , 2008, 102, 348-351.	2.0	32
82	Semantic hyperpriming in schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 193, 82-82.	2.8	2
83	Semantic hyperpriming in schizophrenic patients: Increased facilitation or impaired inhibition in semantic association processing?. <i>Schizophrenia Research</i> , 2007, 89, 243-250.	2.0	27
84	Stability of functional language lateralization over time in schizophrenia patients. <i>Schizophrenia Research</i> , 2007, 94, 197-206.	2.0	47
85	Does hyperpriming reveal impaired spreading of activation in schizophrenia?. <i>Schizophrenia Research</i> , 2007, 97, 289-291.	2.0	6
86	When a schizophrenic deficit becomes a reasoning advantage. <i>Schizophrenia Research</i> , 2006, 84, 359-364.	2.0	14
87	Trastorno perceptivo persistente por alucinaciones despuÃ©s del consumo de psilocibina: un estudio clÃ­nico. <i>European Psychiatry (Ed EspaÃ±ola)</i> , 2006, 13, 141-143.	0.0	0
88	The saccadic component of ocular pursuit is influenced by the predictability of the target motion in humans. <i>Experimental Brain Research</i> , 2006, 168, 294-297.	1.5	6
89	A Concordance Study of Three Electrophysiological Measures in Schizophrenia. <i>American Journal of Psychiatry</i> , 2005, 162, 466-474.	7.2	70
90	Hallucinogen persisting perception disorder after psilocybin consumption: a case study. <i>European Psychiatry</i> , 2005, 20, 458-460.	0.2	47

#	ARTICLE	IF	CITATIONS
91	The subjective quality of life in deficit and nondeficit schizophrenic patients. <i>European Psychiatry</i> , 2005, 20, 346-348.	0.2	9
92	P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia. <i>Psychiatry Research</i> , 2005, 136, 27-34.	3.3	59
93	Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. <i>Psychiatry Research</i> , 2005, 133, 45-55.	3.3	46
94	Atypical hemispheric specialization for language in right-handed schizophrenia patients. <i>Biological Psychiatry</i> , 2005, 57, 1020-1028.	1.3	119
95	Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. <i>Schizophrenia Research</i> , 2005, 78, 157-159.	2.0	31
96	Relationship between performance on the Stroop test and N-acetylaspartate in the medial prefrontal cortex in deficit and nondeficit schizophrenia: preliminary results. <i>Psychiatry Research - Neuroimaging</i> , 2004, 132, 87-89.	1.8	19
97	Verbal learning and memory in schizophrenic and Parkinson's disease patients. <i>Psychiatry Research</i> , 2003, 117, 25-34.	3.3	19
98	Zurdera en los subtipos de esquizofrenia. <i>European Psychiatry (Ed Espa�ola)</i> , 2003, 10, 107-112.	0.0	0
99	Proton Magnetic Resonance Spectroscopy (1H MRS) in Schizophrenia: Investigation of the Right and Left Hippocampus, Thalamus, and Prefrontal Cortex. <i>Schizophrenia Bulletin</i> , 2002, 28, 329-339.	4.3	53
100	Executive/attentional cognitive functions in schizophrenic patients and their parents: a preliminary study. <i>Schizophrenia Research</i> , 2002, 53, 93-99.	2.0	65
101	Sinistrality in schizophrenia. <i>Schizophrenia Research</i> , 2002, 55, 303-306.	2.0	19
102	Borna disease virus and psychiatric disorders. <i>Schizophrenia Research</i> , 2002, 57, 303-305.	2.0	9
103	Sinistrality in subtypes of schizophrenia. <i>European Psychiatry</i> , 2002, 17, 272-277.	0.2	18
104	Objective and Subjective Extrapyrarnidal Side Effects in Schizophrenia: Their Relationships with Negative and Depressive Symptoms. <i>Psychopathology</i> , 2000, 33, 125-130.	1.5	20
105	Plasma 3-Methoxy-4-Hydroxyphenylglycol and Homovanillic Acid Measurements in Deficit and Nondeficit Forms of Schizophrenia. <i>Biological Psychiatry</i> , 1998, 43, 24-30.	1.3	38
106	No association of apolipoprotein epsilon 4 allele with schizophrenia even in cognitively impaired patients. <i>Schizophrenia Research</i> , 1998, 30, 149-153.	2.0	23
107	Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia. <i>Schizophrenia Research</i> , 1997, 23, 259-264.	2.0	46
108	Association study between dopamine D1, D2, D3, and D4 receptor genes and schizophrenia defined by several diagnostic systems. <i>Biological Psychiatry</i> , 1996, 40, 419-421.	1.3	29

#	ARTICLE	IF	CITATIONS
109	Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. <i>Psychiatry Research</i> , 1996, 62, 221-226.	3.3	23
110	No evidence for linkage or association between the dopamine transporter gene and schizophrenia in a French population. <i>Psychiatry Research</i> , 1995, 59, 1-6.	3.3	27
111	A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. <i>Biological Psychiatry</i> , 1994, 36, 230-236.	1.3	42
112	Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. <i>Psychiatry Research</i> , 1994, 51, 215-230.	3.3	53
113	Catecholamines in Autistic Disorder: Effects of Amisulpride and Bromocriptine in a Controlled Crossover Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 1993, 3, 145-156.	1.3	5
114	Amisulpride versus bromocriptine in infantile autism: A controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. <i>Journal of Autism and Developmental Disorders</i> , 1992, 22, 47-60.	2.7	21
115	Functional imaging studies on language lateralization in schizophrenia patients. , 0, , 133-146.		0